Metis Global Partners LLC Has $1.79 Million Stock Holdings in STERIS plc $STE

Metis Global Partners LLC trimmed its position in STERIS plc (NYSE:STE) by 7.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 7,439 shares of the medical equipment provider’s stock after selling 556 shares during the quarter. Metis Global Partners LLC’s holdings in STERIS were worth $1,787,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Spurstone Advisory Services LLC acquired a new stake in STERIS in the second quarter valued at approximately $29,000. Geneos Wealth Management Inc. lifted its holdings in shares of STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 104 shares in the last quarter. Zions Bancorporation National Association UT bought a new position in shares of STERIS in the 1st quarter worth $37,000. Costello Asset Management INC bought a new stake in STERIS during the 1st quarter valued at $45,000. Finally, Atticus Wealth Management LLC acquired a new position in STERIS during the second quarter worth $68,000. Institutional investors own 94.69% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on STE shares. KeyCorp lifted their price objective on shares of STERIS from $277.00 to $288.00 and gave the company an “overweight” rating in a report on Tuesday, July 22nd. Morgan Stanley raised their price target on shares of STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Wall Street Zen raised STERIS from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 14th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of STERIS in a research note on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $273.50.

STERIS Stock Up 0.2%

STERIS stock opened at $264.21 on Tuesday. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $265.56. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The firm’s 50-day simple moving average is $244.36 and its 200 day simple moving average is $239.37. The stock has a market cap of $26.02 billion, a PE ratio of 40.46 and a beta of 1.02.

STERIS (NYSE:STE) last posted its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, topping the consensus estimate of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the firm earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Research analysts predict that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 18th. Investors of record on Tuesday, November 18th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Tuesday, November 18th. STERIS’s dividend payout ratio (DPR) is 36.21%.

Insider Buying and Selling at STERIS

In other news, VP Renato Tamaro sold 3,204 shares of STERIS stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $249.24, for a total transaction of $798,564.96. Following the sale, the vice president directly owned 7,221 shares in the company, valued at $1,799,762.04. The trade was a 30.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of the stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the transaction, the chief executive officer owned 51,096 shares of the company’s stock, valued at approximately $12,356,034.72. The trade was a 0.31% decrease in their position. The SEC filing for this sale provides additional information. 1.07% of the stock is currently owned by insiders.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.